F3 and cancer: In addition, cancer patients have a pro-thrombotic switch of the hemostatic system, which has a complex pathogenesis, including dysfunction of endothelial cells, tumor cells expression of adhesion molecules that bind platelets, endothelial cells and leucocytes and increased production of different procoagulant proteins (tissue factor that generates thrombin, factor VII), inflammatory cytokines (IL-1, TNF-alfa), and procoagulant microparticles that might trigger clotting [35, 36].